Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline treatment of chronic myeloid leukemia (CML). These more potent inhibitors have reduced the rate of disease progression, being able to suppress certain clones that are resistant to imatinib. Dr Saglio highlights how these TKIs induce fast and deep responses; a very important property, even in low-risk patients. This interview was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX.
Benefits of second generation TKIs for CML in the frontline
